Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need.
If Congress follows the Medicaid and CHIP Payment and Access Commission’s (MACPAC) advice, 340B covered entities might see lower ceiling prices on “accelerated approval” drugs, due to 340B prices being based on the Medicaid unit rebate amount and the additional rebate tacked on when a drug’s price has risen faster than inflation.
Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need. If Congress follows the advice, 340B covered entities might see lower ceiling prices on those drugs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
